Wang-Gillam A - Search Results

1

Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ. Badiyan SN, et al. Am J Clin Oncol. 2016 Feb;39(1):1-7. doi: 10.1097/COC.0000000000000003. Am J Clin Oncol. 2016. PMID: 26132367

2

Re: ABO blood group and the risk of pancreatic cancer.

Dandona M, Gao F, Linehan DC, Wang-Gillam A. Dandona M, et al. J Natl Cancer Inst. 2010 Jan 20;102(2):135-7; author reply 137. doi: 10.1093/jnci/djp447. Epub 2009 Dec 17. J Natl Cancer Inst. 2010. PMID: 20019335 No abstract available.

3

Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic.

Wang-Gillam A, Williams K, Novello S, Gao F, Scagliotti GV, Govindan R. Wang-Gillam A, et al. J Clin Oncol. 2010 Aug 20;28(24):3803-7. doi: 10.1200/JCO.2010.28.1824. Epub 2010 Jul 19. J Clin Oncol. 2010. PMID: 20644091

4

Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.

Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC. Goedegebuure P, et al. Curr Cancer Drug Targets. 2011 Jul;11(6):734-51. doi: 10.2174/156800911796191024. Curr Cancer Drug Targets. 2011. PMID: 21599634 Free PMC article. Review.

5

Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer.

Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A. Dandona M, et al. Pancreas. 2011 Aug;40(6):931-7. doi: 10.1097/MPA.0b013e318215a9b1. Pancreas. 2011. PMID: 21747317

6

Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience.

Wang-Gillam A, Abrams RA, Posner MC, Pisters PW, Picozzi VJ. Wang-Gillam A, et al. Am J Clin Oncol. 2013 Dec;36(6):637-43. doi: 10.1097/COC.0b013e31823a53ce. Am J Clin Oncol. 2013. PMID: 22237148 Review.

7

Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?

Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Lim KH, et al. Oncologist. 2012;17(2):192-200. doi: 10.1634/theoncologist.2011-0268. Epub 2012 Jan 16. Oncologist. 2012. PMID: 22250057 Free PMC article. Review.

8

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.

Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. Wang-Gillam A, et al. Invest New Drugs. 2013 Jun;31(3):707-13. doi: 10.1007/s10637-012-9866-y. Epub 2012 Aug 4. Invest New Drugs. 2013. PMID: 22864469 Free PMC article. Clinical Trial.

9

Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.

Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Peddi PF, et al. JOP. 2012 Sep 10;13(5):497-501. doi: 10.6092/1590-8577/913. JOP. 2012. PMID: 22964956 Free article. Clinical Trial.

10

Successful resection after neoadjuvant therapy in pancreatic adenocarcinoma.

Peddi PF, Wang-Gillam A. Peddi PF, et al. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1330-4. doi: 10.6004/jnccn.2012.0139. J Natl Compr Canc Netw. 2012. PMID: 23138162

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters